Angeles Investment Advisors LLC Has $539,000 Stock Position in Sanofi (NASDAQ:SNY)

Angeles Investment Advisors LLC lessened its holdings in shares of Sanofi (NASDAQ:SNY) by 8.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,113 shares of the company’s stock after selling 978 shares during the quarter. Angeles Investment Advisors LLC’s holdings in Sanofi were worth $539,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. POM Investment Strategies LLC acquired a new stake in shares of Sanofi during the second quarter worth about $25,000. Frazier Financial Advisors LLC acquired a new stake in Sanofi during the 4th quarter worth approximately $28,000. Register Financial Advisors LLC bought a new position in Sanofi in the first quarter valued at approximately $29,000. Larson Financial Group LLC boosted its holdings in shares of Sanofi by 480.8% in the first quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after buying an additional 500 shares during the period. Finally, Johnson Financial Group Inc. bought a new stake in shares of Sanofi during the fourth quarter worth $31,000. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Stock Performance

Shares of SNY opened at $57.13 on Monday. The stock has a market capitalization of $144.69 billion, a price-to-earnings ratio of 28.71, a PEG ratio of 1.60 and a beta of 0.60. Sanofi has a 12 month low of $42.63 and a 12 month high of $58.97. The firm has a fifty day simple moving average of $53.67 and a 200 day simple moving average of $50.17. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.93 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. The company had revenue of $10.75 billion during the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The company’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.95 EPS. Research analysts forecast that Sanofi will post 4.25 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on SNY. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 11th. Argus boosted their price target on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, Sanofi has an average rating of “Hold” and an average price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.